{"id":17233,"date":"2017-09-14T12:15:02","date_gmt":"2017-09-14T10:15:02","guid":{"rendered":"http:\/\/localhost:8888\/TG180623\/?page_id=17233"},"modified":"2026-07-06T09:03:09","modified_gmt":"2026-07-06T07:03:09","slug":"portefeuille","status":"publish","type":"page","link":"https:\/\/www.transgene.com\/fr\/portefeuille\/","title":{"rendered":"Portefeuille"},"content":{"rendered":"\n<div id=\"tetContainer\" class=\"wp-block-uagb-container bgImg-02 relativ uagb-block-ec6f09b8 alignfull uagb-is-root-container\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"tgTetContainer\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"degHaut\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"degbas\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"ongletBas\">\n<h1>Portefeuille<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"cont1200\" class=\"wp-block-uagb-container uagb-block-55e06dcf alignfull uagb-is-root-container\"><div class=\"uagb-container-inner-blocks-wrap\">\n<div class=\"wp-block-columns relativ eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"filetWhiteBas\">&nbsp;<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"leadAsset\">\n<h2>Programme phare<\/h2>\n<div id=\"lead\">\n<div>\n<h2><strong>Vaccins Th\u00e9rapeutiques Individualis\u00e9s reposant sur des N\u00e9oantig\u00e8nes (VTIN)<\/strong><\/h2>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"container\">\n<div class=\"accordion panel-group\">\n<div class=\"panel panel-default\" style=\"display: none;\">&nbsp;<\/div>\n<div class=\"panel panel-default bgacc1\">\n<div class=\"panel-heading waves-effect acc1\">\n <a id=\"onglet-TG4050\" href=\"#\" class=\"accordion-link pipeline\">\n<h2 class=\"panel-title\">TG4050, issu de la plateforme <i>myvac<\/i> <sup>\u00ae<\/sup><\/h2>\n<h4><img decoding=\"async\" class=\"logoProgram\" src=\"..\/..\/wp-content\/uploads\/TG4050Adv-fr.svg\" alt=\"program myvac\"><\/h4>\n<div class=\"accArrow\"><i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i><\/div><\/a> wx&lt;\n<\/div>\n<div id=\"collapse-TG4050\" class=\"content-collapse collapsed\">\n<div class=\"panel-body\">\n<div><div class=\"teaser\">\n\nTG4050 est un Vaccin Th\u00e9rapeutique Individualis\u00e9 reposant sur des N\u00e9oantig\u00e8nes et le premier candidat issu de la plateforme <em>myvac<\/em><sup>\u00ae<\/sup>.\n\nIl fait l\u2019objet d\u2019un essai de Phase 1\/2 multicentrique randomis\u00e9 en monoth\u00e9rapie dans le traitement adjuvant des cancers de la t\u00eate et du cou (HNSCC) HPV-n\u00e9gatifs.\n<div class=\"breakSpace\"><\/div>\n<a class=\"colorLien\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04183166\">Plus d&rsquo;information sur clinicaltrial.gov TG4050 NCT04183166<\/a>\n\n<\/div>\n<div class=\"breakSpace\"><\/div>\n<div><\/div>\n<div class=\"teaser\">\n\nEn collaboration avec <img decoding=\"async\" class=\"logoCollabo\" src=\"..\/..\/wp-content\/uploads\/nec-logo-cc-3.svg\" alt=\"NEC\" \/>\n<div class=\"breakSpace\"><\/div>\nEn savoir plus sur\u00a0 <a class=\"colorLien\" href=\"..\/TG4050\">TG4050<\/a>\n<div class=\"breakSpace\"><\/div>\n<a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/481155014?width=640&amp;height=480\" rel=\"wp-video-lightbox\"><b>D\u00e9couvrir TG4050<\/b> <\/a>\n\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"panel panel-default bgacc2\">\n<div class=\"panel-heading waves-effect acc2\"> <a id=\"onglet-add\" href=\"#\" class=\"accordion-link pipeline\">\n<h2 class=\"panel-title\">TG4070, issu de la plateforme <i>myvac<\/i> <sup>\u00ae<\/sup><\/h2>\n<h4><img decoding=\"async\" class=\"logoProgram\" src=\"..\/..\/wp-content\/uploads\/TGxxAdv-fr.svg\" alt=\"program myvac\"><\/h4>\n<div class=\"accArrow\"><i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i><\/div><\/a>\n<\/div>\n<div id=\"collapse-add\" class=\"content-collapse collapsed\">\n<div class=\"panel-body\"><div class=\"teaser\">\n<p>TG4070 est un Vaccin Th\u00e9rapeutique Individualis\u00e9 reposant sur des N\u00e9oantig\u00e8nes et le deuxi\u00e8me candidat issu de la plateforme <em>myvac<\/em><sup>\u00ae<\/sup>.<\/p>\n<p>L\u2019essai de Phase 1 randomis\u00e9 \u00e9value TG4070 en combinaison avec nivolumab chez des patients atteints de cancer du poumon non \u00e0 petites cellules (NSCLC) op\u00e9r\u00e9s.<\/p>\n<div class=\"breakSpace\"><\/div>\n<p><a class=\"colorLien\" href=\"https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2025-520946-31-00?lang=en\">Plus d&rsquo;information sur Clinical Trial in the European Union &#8211; EMA EUCT2025-520946-31-00<\/a><\/p>\n<\/div>\n<div class=\"breakSpace\"><\/div>\n<div><\/div>\n<div class=\"teaser\">\n<div class=\"breakSpace\"><\/div>\n<p>En savoir plus sur\u00a0 <a class=\"colorLien\" href=\"..\/TG4070\">TG4070<\/a><\/p>\n<p><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/1207634895?width=640&amp;height=480\" rel=\"wp-video-lightbox\"><b>D\u00e9couvrir TG4070<\/b> <\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"panel panel-default bgacc3\" style=\"display: none;\">\n<div class=\"panel-heading waves-effect acc3\">\n <a id=\"onglet-add\" href=\"#\" class=\"accordion-link pipeline\">\n<h2 class=\"panel-title\">Placeholder2<\/h2>\n<h4><img decoding=\"async\" class=\"logoProgram\" src=\"..\/..\/wp-content\/uploads\/xxx.svg\" alt=\"program myvac\"> Phase<\/h4>\n<h3>xxxxxx<\/h3>\n<div class=\"accArrow\"><i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i><\/div><\/a>\n<\/div>\n<div class=\"content-collapse collapsed\">\n<div class=\"panel-body\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"otherViralAssets\">\n<h2>Autres actifs bas\u00e9s sur des vecteurs viraux<\/h2>\n<\/div>\n\n\n\n<div class=\"container otherViral\">\n    <div class=\"accordion panel-group\">\n        <div class=\"panel panel-default\" style=\"display:none\"><\/div>\n\n\n          <div class=\"panel panel-default bgacc4\">\n            <div class=\"panel-heading waves-effect accpipe3\">\n                <a id=\"onglet-RD\" href=\"#\" class=\"accordion-link pipeline\">\n                    <h2 class=\"panel-title\">TG-MVA<\/h2>\n                    <h4>\n                        <img decoding=\"async\" class=\"logoProgram2\" src=\"..\/..\/wp-content\/uploads\/TG-MVA-fr.svg\" alt=\"program invirio\">\n                    <\/h4>\n                    <div class=\"accArrow\">\n                        <i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i>\n                    <\/div>\n                <\/a>\n            <\/div>\n            <div id=\"collapse-RD\" class=\"content-collapse collapsed\">\n                <div class=\"panel-body\">\n                    <div class=\"teaser\"> <strong>TG-MVA<\/strong> D\u00e9velopment d\u2019une nouvelle g\u00e9n\u00e9ration de vaccin prophylactique bas\u00e9 sur le MVA (Modified Vaccinia Ankara) contre la variole du singe, mpox.<\/p>\n<p>T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260629_FactSheet_TG-MVA_EN.pdf\"><strong>fiche presse (en anglais)  <\/strong><\/a><\/p>\n<div class=\"teaser\"><\/div>\n<p class=\"eplus-DVrMbh\">Transgene pr\u00e9sente des donn\u00e9es pr\u00e9cliniques de son vaccin innovant contre le mpox produit sur lign\u00e9e cellulaire, TG-MVA.<\/p>\n<p>T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260625_TGMVA_data_FR.pdf\"><strong>communiqu\u00e9 de presse <\/strong><\/a><\/p>\n<div class=\"teaser\"><\/div>\n<p class=\"eplus-DVrMbh\">N. Silvestre, et al.<br \/>\nau World Congress on Infectious Diseases WCID 2026 &#8211; Abstract disponible sur le site du <a href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\"><strong> WCID <\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_WCID_2026.pdf\"><strong>abstract <\/strong><\/a> &#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2026_WCID_TGMVA.pdf\"><strong>pr\u00e9sentation orale <\/strong><\/a><\/p>\n<div class=\"breakSpace\"><\/div>\n<\/div>\n<p>&nbsp;<\/p><p>&nbsp;<\/p>\n                <\/div>\n            <\/div>\n        <\/div>\n        <div class=\"panel panel-default bgacc4\">\n            <div class=\"panel-heading waves-effect accpipe2\">\n                <a id=\"onglet-BT001\" href=\"#\" class=\"accordion-link pipeline\">\n                    <h2 class=\"panel-title\">BT-001<\/h2>\n                    <h4>\n                        <img decoding=\"async\" class=\"logoProgram2\" src=\"..\/..\/wp-content\/uploads\/BT-001-Adv-fr.svg\" alt=\"program invirio\">\n                    <\/h4>\n                    <div class=\"accArrow\">\n                        <i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i>\n                    <\/div>\n                <\/a>\n            <\/div>\n            <div id=\"collapse-mpox\" class=\"content-collapse collapsed\">\n                <div class=\"panel-body\">\n                    <div class=\"teaser\">\n<h4>BT-001 est un virus oncolytique arm\u00e9 exprimant un anticorps anti-CTLA4 et le GM-CSF, issu de la plateforme Invir.IO<sup>\u00ae<\/sup>.<\/h4>\n<p>Il a \u00e9t\u00e9 administr\u00e9 par voie intratumorale, dans une \u00e9tude de Phase 1\/2a multicentrique ouverte, \u00e9valuant des doses ascendantes de BT-001 seul et en combinaison avec pembrolizumab*.<\/p>\n<div class=\"breakSpace\">\n<p><span class=\"legende\"><em>*KEYTRUDA\u00ae est une marque d\u00e9pos\u00e9e de Merck Sharp &amp; Dohme LLC (MDS), filiale de Merck &amp; Co., Inc., Rahway, NJ, USA. <\/em><\/span><\/p>\n<p><a class=\"colorLien\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04725331\">Plus d&rsquo;information sur clinicaltrial.gov <\/a><\/p>\n<p>Une collaboration avec <img decoding=\"async\" class=\"logoCollabo\" src=\"..\/..\/wp-content\/uploads\/BioInvent-1.svg\" alt=\"BioInvent\" \/><\/p>\n<p>En savoir plus sur <a class=\"colorLien\" href=\"bt-001\/\">BT-001 <\/a><\/p>\n<p><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/615834632?width=640&amp;height=480\" rel=\"wp-video-lightbox\"> Mode d&rsquo;action de BT-001<\/a><\/p>\n<\/div>\n<\/div>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n                <\/div>\n            <\/div>\n        <\/div>\n\n        <div class=\"panel panel-default bgacc4\">\n            <div class=\"panel-heading waves-effect accpipe3\">\n                <a id=\"onglet-RD\" href=\"#\" class=\"accordion-link pipeline\">\n                    <h2 class=\"panel-title\">TG6050<\/h2>\n                    <h4>\n                        <img decoding=\"async\" class=\"logoProgram2\" src=\"..\/..\/wp-content\/uploads\/BT-001-Adv-fr.svg\" alt=\"program invirio\">\n                    <\/h4>\n                    <div class=\"accArrow\">\n                        <i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i>\n                    <\/div>\n                <\/a>\n            <\/div>\n            <div id=\"collapse-RD\" class=\"content-collapse collapsed\">\n                <div class=\"panel-body\">\n                    <div class=\"teaser\">\n<h4>TG6050 est virus oncolytique innovant de la plateforme Invir.IO\u00ae arm\u00e9 avec de l\u2019IL-12 et un anticorps anti-CTLA4.<\/h4>\n<p>Il a \u00e9t\u00e9 con\u00e7u pour induire une r\u00e9ponse antitumorale puissante en combinant plusieurs m\u00e9canismes d\u2019action : il cible s\u00e9lectivement les cellules canc\u00e9reuses et permet la production, directement dans la tumeur, de l\u2019IL-12 et d\u2019un anticorps anti-CTLA4, capables d\u2019induire de fortes r\u00e9ponses immunitaires antitumorale.<\/p>\n<div class=\"breakSpace\">\n<p><a class=\"colorLien\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05788926 \">Plus d&rsquo;information sur clinicaltrial.gov <\/a><\/p>\n<p>En savoir plus sur <a class=\"colorLien\" href=\"..\/tg6050\">TG6050<\/a><\/p>\n<p><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/786294781?width=640&amp;height=480\" rel=\"wp-video-lightbox\"> Mode d\u2019action des virus oncolytiques <\/a><\/p>\n<\/div>\n<\/div>\n\n                <\/div>\n            <\/div>\n        <\/div>\n\n        <div class=\"panel panel-default bgacc4\">\n            <div class=\"panel-heading waves-effect accpipe2\">\n                <a id=\"onglet-RD\" href=\"#\" class=\"accordion-link pipeline\">\n                    <h2 class=\"panel-title\">Recherche &amp; Innovation<\/h2>\n                    <h4>\n                        <img decoding=\"async\" class=\"logoProgram2\" src=\"..\/..\/wp-content\/uploads\/RI-Adv-fr.svg\" alt=\"program invirio\">\n                    <\/h4>\n                    <div class=\"accArrow\">\n                        <i class=\"material-icons accordion-toggle-icon\">arrow_downward<\/i>\n                    <\/div>\n                <\/a>\n            <\/div>\n            <div id=\"collapse-RD\" class=\"content-collapse collapsed\">\n                <div class=\"panel-body\">\n                    <div style=\"margin-top: 50px\"><\/div>\n<div id=\"Intro\" class=\"maxWidthTxt\">\u00ab\u00a0<i>Transgene dispose d&rsquo;un portefeuille de projets de recherche pr\u00e9clinique tr\u00e8s prometteur. Notre objectif est d&rsquo;exploiter le potentiel des vecteurs viraux pour mettre au point des immunoth\u00e9rapies de nouvelle g\u00e9n\u00e9ration susceptibles de transformer la mani\u00e8re dont nous traitons les maladies.\u00a0\u00bb <\/i><\/div>\n<div><\/div>\n<p><\/br><\/p>\n<p><\/br><\/p>\n<div><\/div>\n<h4 class=\"btnArrow\"><a class=\"savoirPlusProduits\" href=\"..\/publications-fr\/\">Lien vers les publications scientifiques<\/a><\/h4>\n<h3><\/h3>\n\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns fullWidth relanceContainer eplus-Hznsb4 eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"publications\">\n<div class=\"wp-block-column eplus-n4sHS9 eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-columns eplus-6DgPNw eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-EH3sBp eplus-wrapper TGsousRubrique is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"masked\">\n<div class=\"TitteFullWidth \">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Publications cl\u00e9s (5)<\/h2>\n<div id=\"lastPubli\">\n<div id=\"tgScroll\">\n<div class=\"scroll-container\">\n<div class=\"scroller noPdfCatlist noscroll\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scrollWhite-1.svg\" alt=\"\" width=\"145\" height=\"143\"><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\" title=\"PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe et al.\n<br>SITC 2026<br>\n&#8211; Abstract disponible sur le site du <a href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\"><strong>SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261103_SITC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261107_PosterSITC2026.pdf\"><strong>Poster<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\" title=\"Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>frontiers in Bioengineering and Biotechnology<br>\n&#8211; Article disponible sur le site de <a href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\"><strong>frontiers<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fbioe-14-1943548.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\" title=\"A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al. <br>Article disponible sur <a href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\"><strong>le site de Nature Communications<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/s41467-026-76667-1.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\" title=\"TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">K. Bidet-Huang\n<br>World Vaccine Congress 2026<\/br>\n&#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" title=\"Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>medRxiv<\/br>\nPrepublication disponible sur le site <a href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" ><strong>medRxiv <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/medRxiv_TG4050.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<h4><a href=\"..\/publications-fr\/\"> Voir toutes les publications&nbsp;<\/a><\/h4>\n<\/div>\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">&nbsp;<\/h2>\n<\/div>\n&nbsp;<\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns maxWidth relanceContainer eplus-Hznsb4 eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"faq\">\n<div class=\"wp-block-column eplus-n4sHS9 eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-columns eplus-6DgPNw eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-EH3sBp eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<h1 style=\"margin-left: 10px;\"><br>FAQ Essais cliniques<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n\n\n<div class=\"wp-block-columns tgPatients eplus-wrapper maxWidth is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column TGwarning eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div>\u00a0<\/div>\n<h3>Information importante<\/h3>\n<div>\u00a0<\/div>\n<p>Veuillez noter que les candidats m\u00e9dicament de Transgene ne sont actuellement qu\u2019en phase de tests cliniques, soumis \u00e0 la r\u00e9glementation fix\u00e9e par les autorit\u00e9s comp\u00e9tentes.<\/p>\n<p>Transgene n\u2019est juridiquement pas autoris\u00e9 \u00e0 d\u00e9cider de l\u2019\u00e9ligibilit\u00e9 des patients \u00e0 \u00eatre inclus dans les \u00e9tudes cliniques dont elle est promoteur. Seuls les m\u00e9decins investigateurs responsables des centres d\u2019\u00e9tudes cliniques disposent de la comp\u00e9tence \u00e0 d\u00e9cider si un patient r\u00e9pond aux crit\u00e8res d\u2019inclusion et d\u2019exclusion au regard du protocole d\u2019\u00e9tude clinique correspondant.<\/p>\n<p>Veuillez \u00e9galement noter que Transgene ne peut communiquer ou interagir avec les patients, sur le d\u00e9roulement ou la progression des \u00e9tudes. Vous trouverez toutes les informations accessibles au public sur le site clinicaltrials.gov.<\/p>\n<p>Politique d\u2019acc\u00e8s \u00e9largi : <u><a href=\"https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-access\">Expanded Access | FDA<\/a><\/u><\/p>\n<p>Clinicaltrial.gov:<a style=\"text-decoration: underline;\" href=\"https:\/\/clinicaltrials.gov\/\"> Home | ClinicalTrials.gov<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column tgFAQ eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div>\u00a0<\/div>\n\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-coblocks-accordion\">\n<div class=\"wp-block-coblocks-accordion-item\"><details><summary class=\"wp-block-coblocks-accordion-item__title\">Qu&rsquo;est-ce qu&rsquo;un essai clinique ?<\/summary><div class=\"wp-block-coblocks-accordion-item__content\">\n<p>Les essais cliniques, ou \u00e9tudes cliniques, ont pour but l\u2019\u00e9valuation de nouveaux traitements, notamment leur s\u00e9curit\u00e9 et leur efficacit\u00e9. Ils sont obligatoires avant l\u2019autorisation et la commercialisation de nouveaux traitements.<\/p>\n<\/div><\/details><\/div>\n<div class=\"wp-block-coblocks-accordion-item\"><details><summary class=\"wp-block-coblocks-accordion-item__title\">Qui peut participer \u00e0 un essai clinique ?<\/summary><div class=\"wp-block-coblocks-accordion-item__content\">\n<p>Chaque essai clinique se d\u00e9roule suivant un protocole d\u00e9fini en amont et valid\u00e9 par les autorit\u00e9s de sant\u00e9 et diff\u00e9rents comit\u00e9s afin de prot\u00e9ger l\u2019int\u00e9r\u00eat des patients. Pour entrer dans un essai clinique, le patient doit remplir un certain de nombre de crit\u00e8res, propres \u00e0 chaque essai, contenus dans le protocole.<\/p>\n<\/div><\/details><\/div>\n<div class=\"wp-block-coblocks-accordion-item\"><details><summary class=\"wp-block-coblocks-accordion-item__title\">Participer \u00e0 une \u00e9tude clinique : Quels sont les avantages et les risques ?<\/summary><div class=\"wp-block-coblocks-accordion-item__content\">\n<p>Les risques comme les avantages li\u00e9s \u00e0 la participation \u00e0 un essai clinique sont d\u00e9crits dans le protocole de recherche et dans le document de consentement \u00e9clair\u00e9. L\u2019\u00e9quipe m\u00e9dicale les explique \u00e9galement au patient, qui est libre de poser ses questions.<br><\/p>\n<p>Participer \u00e0 un essai clinique, c\u2019est la possibilit\u00e9 d\u2019avoir acc\u00e8s \u00e0 un traitement innovant, avant qu\u2019il ne soit largement disponible. C\u2019est aussi un encadrement sp\u00e9cifique de la prise en charge et un suivi adapt\u00e9 et rigoureux, pendant et apr\u00e8s la fin du traitement.<br><\/p>\n<p>Comme pour tout traitement, les candidats-m\u00e9dicaments utilis\u00e9s dans les essais cliniques peuvent entra\u00eener des effets secondaires. Dans certains essais cliniques, il est aussi possible de faire partie du groupe de contr\u00f4le et de ne pas recevoir le traitement innovant.<\/p>\n<\/div><\/details><\/div>\n<div class=\"wp-block-coblocks-accordion-item\"><details><summary class=\"wp-block-coblocks-accordion-item__title\">Comment participer \u00e0 un essai clinique ?<\/summary><div class=\"wp-block-coblocks-accordion-item__content\">\n<p>Tout d\u2019abord, le patient doit discuter de ce sujet avec son m\u00e9decin traitant et son oncologue. Celui-ci pourra ensuite se rapprocher des m\u00e9decins en charge de l\u2019essai (investigateur).<\/p>\n<\/div><\/details><\/div>\n\n<div class=\"wp-block-coblocks-accordion-item\"><details><summary class=\"wp-block-coblocks-accordion-item__title\">Plus d&rsquo;information<\/summary><div class=\"wp-block-coblocks-accordion-item__content\">\n<p>Plus d\u2019informations sur le site de l&rsquo;<a href=\"http:\/\/www.e-cancer.fr\/Comprendre-prevenir-depister\/Comprendre-la-recherche\/A-quoi-sert-la-recherche\/Les-essais-cliniques#toc-tous-les-malades-sont-ils-concern-s-\" style=\"text-decoration:underline\">Institut national du cancer (INCa)<\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-accessExpanded\" style=\"text-decoration:underline\"> Access | FDA<\/a><\/p>\n<\/div><\/details><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Portefeuille &nbsp; Programme phare Vaccins Th\u00e9rapeutiques Individualis\u00e9s reposant sur des N\u00e9oantig\u00e8nes (VTIN) &nbsp; TG4050, issu de la plateforme myvac \u00ae arrow_downward wx&lt; TG4070, issu de la plateforme myvac \u00ae arrow_downward Placeholder2 Phase xxxxxx arrow_downward Autres actifs bas\u00e9s sur des vecteurs viraux TG-MVA arrow_downward &nbsp; &nbsp; BT-001 arrow_downward TG6050 arrow_downward Recherche &amp; Innovation arrow_downward Publications cl\u00e9s&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/portefeuille\/\">Poursuivre la lecture <span class=\"screen-reader-text\">Portefeuille<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":25,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-17233","page","type-page","status-publish","hentry","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"Portefeuille &nbsp; Programme phare Vaccins Th\u00e9rapeutiques Individualis\u00e9s reposant sur des N\u00e9oantig\u00e8nes (VTIN) &nbsp; TG4050, issu de la plateforme myvac \u00ae arrow_downward wx&lt; TG4070, issu de la plateforme myvac \u00ae arrow_downward Placeholder2 Phase xxxxxx arrow_downward Autres actifs bas\u00e9s sur des vecteurs viraux TG-MVA arrow_downward &nbsp; &nbsp; BT-001 arrow_downward TG6050 arrow_downward Recherche &amp; Innovation arrow_downward Publications cl\u00e9s&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/17233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=17233"}],"version-history":[{"count":61,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/17233\/revisions"}],"predecessor-version":[{"id":41311,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/17233\/revisions\/41311"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=17233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}